Cargando…
Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation
Smoking is the largest preventable cause of morbidity and mortality in the world. Although there are effective pharmacologic and behavioral treatments for smoking cessation, our inability to objectively quantify smokers’ progress in decreasing smoking has been a barrier to both clinical and research...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822186/ https://www.ncbi.nlm.nih.gov/pubmed/27092088 http://dx.doi.org/10.3389/fpsyt.2016.00055 |
_version_ | 1782425729720385536 |
---|---|
author | Philibert, Robert Hollenbeck, Nancy Andersen, Eleanor McElroy, Shyheme Wilson, Scott Vercande, Kyra Beach, Steven R. H. Osborn, Terry Gerrard, Meg Gibbons, Frederick X. Wang, Kai |
author_facet | Philibert, Robert Hollenbeck, Nancy Andersen, Eleanor McElroy, Shyheme Wilson, Scott Vercande, Kyra Beach, Steven R. H. Osborn, Terry Gerrard, Meg Gibbons, Frederick X. Wang, Kai |
author_sort | Philibert, Robert |
collection | PubMed |
description | Smoking is the largest preventable cause of morbidity and mortality in the world. Although there are effective pharmacologic and behavioral treatments for smoking cessation, our inability to objectively quantify smokers’ progress in decreasing smoking has been a barrier to both clinical and research efforts. In prior work, we and others have shown that DNA methylation at cg05575921, a CpG residue in the aryl hydrocarbon receptor repressor (AHRR), can be used to determine smoking status and infer cigarette consumption history. In this study, we serially assessed self-report and existing objective markers of cigarette consumption in 35 subjects undergoing smoking cessation therapy, then quantified DNA methylation at cg05575921 at study entry and three subsequent time points. Five subjects who reported serum cotinine and exhaled carbon monoxide verified smoking abstinence for the 3 months prior to study exit averaged a 5.9% increase in DNA methylation at cg05575921 (p < 0.004) over the 6-month study. Although the other 30 subjects did not achieve smoking cessation at the 6-month time point, their self-reported reduction of cigarette consumption (mean = 6 cigarettes/day) was associated with a 2.8% increase DNA methylation at cg05575921 (p < 0.05). Finally, a survey of subjects as they exited the study demonstrated strong support for the clinical use of epigenetic biomarkers. We conclude that AHRR methylation status is a quantifiable biomarker for progress in smoking cessation that could have substantial impact on both smoking cessation treatment and research. |
format | Online Article Text |
id | pubmed-4822186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48221862016-04-18 Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation Philibert, Robert Hollenbeck, Nancy Andersen, Eleanor McElroy, Shyheme Wilson, Scott Vercande, Kyra Beach, Steven R. H. Osborn, Terry Gerrard, Meg Gibbons, Frederick X. Wang, Kai Front Psychiatry Psychiatry Smoking is the largest preventable cause of morbidity and mortality in the world. Although there are effective pharmacologic and behavioral treatments for smoking cessation, our inability to objectively quantify smokers’ progress in decreasing smoking has been a barrier to both clinical and research efforts. In prior work, we and others have shown that DNA methylation at cg05575921, a CpG residue in the aryl hydrocarbon receptor repressor (AHRR), can be used to determine smoking status and infer cigarette consumption history. In this study, we serially assessed self-report and existing objective markers of cigarette consumption in 35 subjects undergoing smoking cessation therapy, then quantified DNA methylation at cg05575921 at study entry and three subsequent time points. Five subjects who reported serum cotinine and exhaled carbon monoxide verified smoking abstinence for the 3 months prior to study exit averaged a 5.9% increase in DNA methylation at cg05575921 (p < 0.004) over the 6-month study. Although the other 30 subjects did not achieve smoking cessation at the 6-month time point, their self-reported reduction of cigarette consumption (mean = 6 cigarettes/day) was associated with a 2.8% increase DNA methylation at cg05575921 (p < 0.05). Finally, a survey of subjects as they exited the study demonstrated strong support for the clinical use of epigenetic biomarkers. We conclude that AHRR methylation status is a quantifiable biomarker for progress in smoking cessation that could have substantial impact on both smoking cessation treatment and research. Frontiers Media S.A. 2016-04-06 /pmc/articles/PMC4822186/ /pubmed/27092088 http://dx.doi.org/10.3389/fpsyt.2016.00055 Text en Copyright © 2016 Philibert, Hollenbeck, Andersen, McElroy, Wilson, Vercande, Beach, Osborn, Gerrard, Gibbons and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Philibert, Robert Hollenbeck, Nancy Andersen, Eleanor McElroy, Shyheme Wilson, Scott Vercande, Kyra Beach, Steven R. H. Osborn, Terry Gerrard, Meg Gibbons, Frederick X. Wang, Kai Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation |
title | Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation |
title_full | Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation |
title_fullStr | Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation |
title_full_unstemmed | Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation |
title_short | Reversion of AHRR Demethylation Is a Quantitative Biomarker of Smoking Cessation |
title_sort | reversion of ahrr demethylation is a quantitative biomarker of smoking cessation |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822186/ https://www.ncbi.nlm.nih.gov/pubmed/27092088 http://dx.doi.org/10.3389/fpsyt.2016.00055 |
work_keys_str_mv | AT philibertrobert reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT hollenbecknancy reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT anderseneleanor reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT mcelroyshyheme reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT wilsonscott reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT vercandekyra reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT beachstevenrh reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT osbornterry reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT gerrardmeg reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT gibbonsfrederickx reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation AT wangkai reversionofahrrdemethylationisaquantitativebiomarkerofsmokingcessation |